1. Home
  2. SNDX vs KFRC Comparison

SNDX vs KFRC Comparison

Compare SNDX & KFRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • KFRC
  • Stock Information
  • Founded
  • SNDX 2005
  • KFRC 1962
  • Country
  • SNDX United States
  • KFRC United States
  • Employees
  • SNDX N/A
  • KFRC N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • KFRC Professional Services
  • Sector
  • SNDX Health Care
  • KFRC Consumer Discretionary
  • Exchange
  • SNDX Nasdaq
  • KFRC Nasdaq
  • Market Cap
  • SNDX 1.1B
  • KFRC 770.2M
  • IPO Year
  • SNDX 2016
  • KFRC 1995
  • Fundamental
  • Price
  • SNDX $9.12
  • KFRC $40.66
  • Analyst Decision
  • SNDX Strong Buy
  • KFRC Buy
  • Analyst Count
  • SNDX 11
  • KFRC 3
  • Target Price
  • SNDX $35.91
  • KFRC $53.67
  • AVG Volume (30 Days)
  • SNDX 1.8M
  • KFRC 134.6K
  • Earning Date
  • SNDX 07-31-2025
  • KFRC 07-28-2025
  • Dividend Yield
  • SNDX N/A
  • KFRC 3.78%
  • EPS Growth
  • SNDX N/A
  • KFRC N/A
  • EPS
  • SNDX N/A
  • KFRC 2.56
  • Revenue
  • SNDX $43,722,000.00
  • KFRC $1,383,447,000.00
  • Revenue This Year
  • SNDX $426.77
  • KFRC N/A
  • Revenue Next Year
  • SNDX $98.31
  • KFRC $4.06
  • P/E Ratio
  • SNDX N/A
  • KFRC $16.15
  • Revenue Growth
  • SNDX N/A
  • KFRC N/A
  • 52 Week Low
  • SNDX $8.58
  • KFRC $35.50
  • 52 Week High
  • SNDX $25.07
  • KFRC $71.48
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 38.53
  • KFRC 49.22
  • Support Level
  • SNDX $11.00
  • KFRC $39.56
  • Resistance Level
  • SNDX $11.83
  • KFRC $41.56
  • Average True Range (ATR)
  • SNDX 0.54
  • KFRC 0.94
  • MACD
  • SNDX -0.12
  • KFRC 0.06
  • Stochastic Oscillator
  • SNDX 18.12
  • KFRC 50.63

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About KFRC Kforce Inc.

Kforce Inc is a solutions firm specializing in technology, finance and accounting, and other professional staffing services. The company operates two business segments: 1) In technology segment it provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. 2) In FA segment company offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting business and cost analysis; and taxation and treasury. The majority of revenue is earned through the technology segment.

Share on Social Networks: